Onkologie. 2011:5(5):298-300

Role of cetuximab in treating metastatic colorectal cancer

Luboš Holubec, Vít Martin Matějka, Václav Liška, Jiří Salvét, Jana Dreslerová, Vladimír Třeška, Jindřich Fínek
Komplexní onkologické centrum a Chirurgická klinika FN a LF UK v Plzni

Targeted biological therapy is becoming a standard in personalized medicine in patients with advanced cancer. An example of personalized

oncology in patients with metastatic colorectal cancer is the treatment with cetuximab, an anti-EGFR antibody, in patients with

an unmutated form of the K-ras gene. The authors deal with the role of cetuximab in treating metastatic colorectal cancer with a focus

on the treatment of hepatic metastases.

Keywords: K-ras, cetuximab, colorectal cancer, hepatic metastases

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holubec L, Matějka VM, Liška V, Salvét J, Dreslerová J, Třeška V, Fínek J. Role of cetuximab in treating metastatic colorectal cancer. Onkologie. 2011;5(5):298-300.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zavoral M, Suchánek S, Závada F, a kol. Colorectal cancer screening in Europe. J. Gastroenterol 2009; 15: 5907-5915. Go to original source...
    2. Ryska M, Pantoflíček J, Dušek L. Chirurgická léčba jaterních metastáz kolokrektálního původu v České republice: současný celostátní survey. Rozhl Chir 2010; 89(2): 100-108. Go to PubMed...
    3. Holubec L, Matějka VM. Role cetuximabu ve 2. linii terapie metastatického kolorektálního karcinomu s následnou udržovací monoterapií monoklonální protilátkou cetuximab Onkologie 2011; 5(2): 99-101.
    4. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39(10): 1348-1354. Go to original source... Go to PubMed...
    5. Kocáková I, Kocák I, Němeček R. Cetuximab a irinotecan v léčbě chemorezistentního metastazujícího kolorektálního karcinomu. Onkologie 2009; 3(5): 303-307.
    6. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13(6): 506-513. Go to original source... Go to PubMed...
    7. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6(9): 3739-3747.
    8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 Jul 22; 351(4): 337-345. Go to original source... Go to PubMed...
    9. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13(12): 1841-1851. Go to original source... Go to PubMed...
    10. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 2011-2009. Go to original source... Go to PubMed...
    11. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22(7): 1535-1546. Go to original source... Go to PubMed...
    12. Česká onkologická společnost. Zásady cytostatické léčby maligních onkologických onemocnění. 13. vydání 2011.
    13. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; (33): 5335-5343. Go to original source... Go to PubMed...
    14. Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S, Lerzo G. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 2010; 9(5): 282-289. Go to original source... Go to PubMed...
    15. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2010; 21(7): 1537-1545. Go to original source... Go to PubMed...
    16. Humblet Y, Peeters M, Geldetblom H, et al. Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetics (PK), pharmacodynamics (PD) and efficacy data from the EVEREST study. Eur J Cancer 2007; 4(Suppl 5): Abstract 3040. Go to original source...
    17. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 2(14): 2311-2319. Go to original source... Go to PubMed...
    18. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360(14): 1408-1417. Go to original source... Go to PubMed...
    19. Oliverius M, Šafanda M, Petruželka L. Soudobý pohled na léčbu jaterních metastáz kolorektálního karcinomu. Klin Onkol 2010; 23(2): 73-77. Go to PubMed...
    20. Třeška V, Skalický T, Sutnar A, Liška V. Chirurgická léčba jaterních metastáz kolorektálního karcinomu. Rozhledy v chirurgii 2009; 88(2): 69-74. Go to PubMed...
    21. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23(9): 2038-2048. Go to original source... Go to PubMed...
    22. Kubala E, Petruželka L, Sedláčková E. Chemoterapie a biologická léčba v komplexní léčbě karcinomu tlustého střeva a konečníku. Kdy, proč, jak? Rozhledy v chirurgii 2009; 88(6): 303-307. Go to PubMed...
    23. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200(6): 845-53. Go to original source... Go to PubMed...
    24. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7(8): 1082-8. Go to original source... Go to PubMed...
    25. Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, Jaeck D, Chenard MP. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol 2010; 36(6): 575-582. Go to original source... Go to PubMed...
    26. Liška V, Třeška V, Holubec L, et al. Immediately preoperative use of biological therapy does not influence liver regeneration after large resection - Porcine Experimental Model with monoclonal antibody against Epidermal growth factor. Anticancer Research 2011, in press.
    27. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11(1): 38-47. Go to original source... Go to PubMed...
    28. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103(10): 1542-1547. Go to original source... Go to PubMed...
    29. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143. Go to original source... Go to PubMed...
    30. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelinesin Oncology v.1/2012, USA http://www.nccn.com.
    31. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12(7): 642-653. Go to original source... Go to PubMed...
    32. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377(9783): 2103-2114. Go to original source... Go to PubMed...
    33. Weber T, Link KH. Multimodal therapy for colon cancer: state of the art. Zentralbl Chir 2011;136(4): 325-333. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.